Abstract:While synergistic drug combinations are more effective at fighting tumors with complex pathophysiology, preference compensating mechanisms, and drug resistance, the identification of novel synergistic drug combinations, especially complex higher-order combinations, remains challenging due to the size of combination space. Even though certain computational methods have been used to identify synergistic drug combinations in lieu of traditional in vitro and in vivo screening tests, the majority of previously published work has focused on predicting synergistic drug pairs for specific types of cancer and paid little attention to the sophisticated high-order combinations. The main objective of this study is to develop a deep learning-based approach that integrated multi-omics data to predict novel synergistic multi-drug combinations (DeepMDS) in a given cell line. To develop this approach, we firstly created a dataset comprising of gene expression profiles of cancer cell lines, target information of anti-cancer drugs, and drug response against a large variety of cancer cell lines. Based on the principle of a fully connected feed forward Deep Neural Network, the proposed model was constructed using this dataset, which achieved a high performance with a Mean Square Error (MSE) of 2.50 and a Root Mean Squared Error (RMSE) of 1.58 in the regression task, and gave the best classification accuracy of 0.94, an area under the Receiver Operating Characteristic curve (AUC) of 0.97, a sensitivity of 0.95, and a specificity of 0.93. Furthermore, we utilized three breast cancer cell subtypes (MCF-7, MDA-MD-468 and MDA-MB-231) and one lung cancer cell line A549 to validate the predicted results of our model, showing that the predicted top-ranked multi-drug combinations had superior anti-cancer effects to other combinations, particularly those that were widely used in clinical treatment. Our model has the potential to increase the practicality of expanding the drug combinational space and to leverage its capacity to prioritize the most effective multi-drug combinational therapy for precision oncology applications.

Developing an Agent-Based Drug Model to Investigate the Synergistic Effects of Drug Combinations

Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies

Multi-scale Agent-Based Modeling on Melanoma and Its Related Angiogenesis Analysis.

Drug-loaded nanoparticles for cancer therapy: a high-throughput multicellular agent-based modeling study

An Integrated Multiscale Mechanistic Model for Cancer Drug Therapy

Searching Synergistic Dose Combinations for Anticancer Drugs

SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation

Prediction of Synergistic Anti-Cancer Drug Combinations Based on Drug Target Network and Drug Induced Gene Expression Profiles

Predicting drug synergy using a network propagation inspired machine learning framework

Fusing Micro- and Macro-Scale Information to Predict Anticancer Synergistic Drug Combinations

Synergistic Drug Combination Prediction by Integrating Multi-omics Data in Deep Learning Models

Advances in computational approaches in identifying synergistic drug combinations.

Discovering Synergistic Drug Combination from a Computational Perspective

MMFSyn: A Multimodal Deep Learning Model for Predicting Anticancer Synergistic Drug Combination Effect

SNRMPACDC: computational model focused on Siamese network and random matrix projection for anticancer synergistic drug combination prediction

Simulating non-small cell lung cancer with a multiscale agent-based model

A landscape of response to drug combinations in non-small cell lung cancer

Anti-cancer Drug Synergy Prediction in Understudied Tissues using Transfer Learning

MFSynDCP: multi-source feature collaborative interactive learning for drug combination synergy prediction

How to Predict Effective Drug Combinations - Moving beyond Synergy Scores